TY - JOUR
T1 - Dementia in China
T2 - epidemiology, clinical management, and research advances
AU - Group for the Project of Dementia Situation in China
AU - Jia, Longfei
AU - Quan, Meina
AU - Fu, Yue
AU - Zhao, Tan
AU - Li, Yan
AU - Wei, Cuibai
AU - Tang, Yi
AU - Qin, Qi
AU - Wang, Fen
AU - Qiao, Yuchen
AU - Shi, Shengliang
AU - Wang, Yan Jiang
AU - Du, Yifeng
AU - Zhang, Jiewen
AU - Zhang, Junjian
AU - Luo, Benyan
AU - Qu, Qiumin
AU - Zhou, Chunkui
AU - Gauthier, Serge
AU - Jia, Jianping
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/1
Y1 - 2020/1
N2 - China has the largest population of patients with dementia in the world, imposing a heavy burden on the public and health care systems. More than 100 epidemiological studies on dementia have been done in China, but the estimates of the prevalence and incidence remain inconsistent because of the use of different sampling methods. Despite improved access to health services, inadequate diagnosis and management for dementia is still common, particularly in rural areas. The Chinese Government issued a new policy to increase care facilities for citizens older than 65 years, but most patients with dementia still receive care at home. Western medicines for dementia symptoms are widely used in China, but many patients choose Chinese medicines even though they have little evidence supporting efficacy. The number of clinical trials of Chinese and western medicines has substantially increased as a result of progress in research on new antidementia drugs but international multicentre studies are few in number. Efforts are needed to establish a national system of dementia care enhance training in dementia for health professionals, and develop global collaborations to prevent and cure this disease.
AB - China has the largest population of patients with dementia in the world, imposing a heavy burden on the public and health care systems. More than 100 epidemiological studies on dementia have been done in China, but the estimates of the prevalence and incidence remain inconsistent because of the use of different sampling methods. Despite improved access to health services, inadequate diagnosis and management for dementia is still common, particularly in rural areas. The Chinese Government issued a new policy to increase care facilities for citizens older than 65 years, but most patients with dementia still receive care at home. Western medicines for dementia symptoms are widely used in China, but many patients choose Chinese medicines even though they have little evidence supporting efficacy. The number of clinical trials of Chinese and western medicines has substantially increased as a result of progress in research on new antidementia drugs but international multicentre studies are few in number. Efforts are needed to establish a national system of dementia care enhance training in dementia for health professionals, and develop global collaborations to prevent and cure this disease.
UR - https://www.scopus.com/pages/publications/85074468245
U2 - 10.1016/S1474-4422(19)30290-X
DO - 10.1016/S1474-4422(19)30290-X
M3 - 文献综述
C2 - 31494009
AN - SCOPUS:85074468245
SN - 1474-4422
VL - 19
SP - 81
EP - 92
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 1
ER -